2-AMINOETHANESULFONIC ACID/ZINC COMPLEX

Abstract: A 2-aminoethanesulfonic acid/zinc complex represented by general formula (I) (wherein M represents an alkali metal atom), a process for the production thereof from 2-aminoethanesulfonic acid, and the use thereof for treating hepatitis and ulcer and ameliorating hepatic functions. This complex has not only excellent activities of treating hepatitis, ulcer, etc., and inhibiting hepatic disorder, but also an activity of protecting and repairing gastrointestinal mucosae.

Description: The present invention relates to a novel 2-aminoethanesulfonic acid zinc complex, to a process for producing the same and to an anti-hepatitis agent, liver function improving agent and anti-ulcer agent, which individually contain the same as an active ingredient. 2-Aminoethanesulfonic acid (taurine) is known to possess liver-function protecting activity, but has weak physiological activity. The present inventors have found that a novel 2-aminoethanesulfonic acid zinc complex can be synthesized by reacting 2-aminoethanesulfonic acid with an alkali agent and zinc compound or by reacting an alkali metal salt of 2-aminoethanesulfonic acid with bis(2-aminoethanesulfonic acid) zinc salt, and that the complex possesses marked anti-hepatitis, liver-function improving and anti-ulcer activities. EP-A-0206692 discloses solid or semi-solid pharmaceutical compositions containing physiologically acceptable zinc compounds capable of sustaining release of zinc ions for topical application to external wounds to enhance tissue regeneration. Exemplified zinc compounds include zinc taurine but, unlike the complex of the present invention, zinc taurine is water-soluble (see EP-A-0206692 at, for example, column 2, lines 35/47 and column 10, lines 22/26). The present invention relates to a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom), to a process for producing the said complex from 2-aminoethanesulfonic acid and to use of the said complex as an anti-hepatitis agent, liver-function improving agent and anti-ulcer agent. As the alkali metal atom represented by M in the general formula (I), there may be mentioned for example sodium and potassium. The complex of the general formula (I) can be produced, for example, by reacting 2-aminoethanesulfonic acid (1 mole) with an alkali agent (1 mole) and zinc compound (0.25 mole). The said reaction, when conducted with use of the zinc compound (0.5 mole), was also found to give the complex (I) in the same yield. Referring to the alkali agent, there is preferably used alkali metal alcoholates such as sodium methylate, sodium ethylate, potassium methylate, potassium ethylate and potassium t-butoxide, while as the zinc compound, zinc acetate is preferred but other zinc compounds may be utilized. The reaction is usually carried out in a suitable solvent such as methanol and ethanol at room temperature or under heating for several minutes to several hours, and after the conclusion of the reaction, the reaction product can be purified by conventional means. The complex (I) can be produced by reacting an alkali metal salt of 2-aminoethanesulfonic acid (1 mole) with bis(2-aminoethanesulfonic acid) zinc salt (0.5 mole). The alkali metal can be, for example, sodium or potassium. The reaction is normally conducted in a suitable solvent such as methanol and ethanol at room temperature or under heating for several minutes to several hours and after the reaction is completed, the reaction product can be purified by conventional means. The complex (I) exhibits improved anti-hepatitis, liver-function improving and anti-ulcer activities, and has low toxicity. The complex can be administered orally or parenterally either per se or after being admixed with, for example, pharmacologically acceptable excipients, carriers, or diluents and processed into various dosage forms such as tablets, capsules, granules, powders and syrups. The dosage amount varies with, for example, the symptoms, age and body weight of patients, and route of administration but the complex is usually administered to human adults orally at a single dose of 100 to 200 mg, twice to three times a day. Described below are examples and test examples of this invention to illustrate the present invention in detail. Example 1 To 12.5 g (0.1 mole) of 2-aminoethanesulfonic acid was added 120 ml of dried methanol, and a solution of 19.3 ml (0.1 mole) of 28% sodium methylate in 50 ml of dried methanol was added dropwise to the resulting solution under stirring at 60 to 70°C, followed by stirring continued under the same conditions. Two hours later, a solution of 5.5 g (0.025 mole) of zinc acetate dihydrate in 60 ml of dried methanol was added dropwise to the solution mixture, and the reaction solution was allowed to cool and stirred for 1 hour. The crystals which precipitated were recovered by filtration and washed with dried methanol to give 14.2 g (yield of 93.4 %) of zinc-[bis(2-aminoethanesulfonic acid) bis(sodium 2-aminoethanesulfonate)] in the form of colorless crystals. m.p. 284°C (decomp.). Elemental analysis (%): C 8 H 24 N 4 S 4 O 12 Na 2 Zn Calcd., C:15.80, H:3.98, N:9.22, Na:7.56, Zn:10.76 Found , C:15.87, H:3.97, N:9.21, Na:7.19, Zn:11.20 IR (KBr, cm -1 ); 3449, 3304, 3260, 2988, 2944, 1587, 1456, 1408, 1384, 1209, 1152, 1126, 1044, 984. Example 2 To 12.5 g (0.1 mole) of 2-aminoethanesulfonic acid was added 120 ml of dried methanol, and a solution of 23.4 ml (0.1 mole) of 30% potassium methylate in 50 ml of dried methanol was added dropwise to the solution under stirring at 60 to 70°C, followed by stirring continued under the same conditions. Two hours later, a solution of 5.5 g (0.025 mole) of zinc acetate dihydrate in 60 ml of dried methanol was added dropwise to the solution mixture, and the reaction mixture was allowed to cool and stirred for another 1 hour. The crystals which precipitated were recovered by filtration and washed with dried methanol to give 14.7 g (yield of 91.9 %) of zinc-[bis(2-aminoethanesulfonic acid) bis(potassium 2-aminoethansulfonate)] in the form of colorless crystals. m.p. 274°C (decomp.). Elemental analysis (%): C 8 H 24 N 4 S 4 O 12 K 2 Zn Calcd., C:15.01, H:3.78, N:8.75, K:12.22, Zn:10.21 Found , C:15.02, H:3.76, N:8.79, K:11.80, Zn:10.60 IR (KBr, cm -1 ); 3447, 3295, 3261, 2976, 2937, 1591, 1459, 1405, 1388, 1208, 1152, 1128, 1043, 985. Example 3 To 12.5 g (0.1 mole) of 2-aminoethanesulfonic acid were added 150 ml of dried methanol and 19.3 ml (0.1 mole) of 28% sodium methylate, followed by stirring for 30 min. Then, 15.7 g (0.05 mole) of bis(2-aminoethanesulfonic acid) zinc salt was added to the solution, followed by stirring at 50 to 60°C for 5 hours. The precipitate was recovered by filtration and washed with dried methanol to give 27.5 g (yield of 90.5 %) of zinc-[bis(2-aminoethanesulfonic acid)· bis(sodium 2-aminoethanesulfonate)] in the form of colorless crystals. m.p., 284°C (decomp.). Elemental analysis (%): C 8 H 24 N 4 S 4 O 12 Na 2 Zn Calcd., C:15.80, H:3.98, N:9.22, Na:7.56, Zn:10.76 Found, C:15.73, H:4.00, N:9.23, Na:7.31, Zn:11.28 IR (KBr, cm -1 ); 3446, 3303, 3260, 2985, 2944, 1588, 1456, 1408, 1384, 1209, 1152, 1126, 1044, 984. Test Example Test substance: Zinc-[bis(2-aminoethanesulfonic acid)·bis(sodium 2-aminoethanesulfonate)] (hereinafter referred to briefly as "FTZ") 1. Anti-hepatitis test (1) Liver disorder (hepatopathy) in mice A group of 8 dyy-strain male mice (weighing 23 to 25 g) kept fasting from the previous day was treated by intraperitoneal injection of a 25 % solution of carbon tetrachloride in olive oil at a dose of 0.1 ml/g body weight and thereafter allowed free access to food. Three hours after the administration of carbon tetrachloride, the mice were given a 1.0 mg/ml concentrated suspension of the test substance, as prepared in conjunction with powdered gum arabic, by intra-peritoneal injection at a dose of 0.1 ml/body weight. Twenty four hours after the administration of carbon tetrachloride, blood samples were drawn from the mice under anesthesia with ether through the abdominal. descending aorta. The collected blood was centrifuged at a rate of 3,000 rpm for 15 min, followed by measurement of the activities of alanine transaminase (ALT), aspartate transaminase (AST) and lactate dehydrogenase (LDH) by means of the Lippie method. The results are shown in Table 1. Test substance ALT IU, mean±S.D. AST IU, mean±S.D. LDH IU, mean±S.D. Normal group 107.1±54.7 86.6±29.2 884±335.2 Treated group 11408±4240.1 10663±2493.2 44280±9637 FTZ 4265.7±1347.6 3215.8±967.7 15865±5300.8 Thiopronine 4941.2±1537.7 4884.5±1097.5 26789±9753 Glutathione 19423.1±1042.3 9643.6±3874.3 32392±7906 Glycyrrhizin 8339.3±2420.1 8949.6±4530.0 26457±11086 (2) Disorder of the isolated liver cells a. Carbon tetrachloride Isolated liver cells of rats were prepared by means of Segren's collagenase irrigation method, whereby a liver cell suspension was prepared to a concentration of 6 x 10 8 liver cells/ml. Into 2 ml of the suspension in an Erlenmeyer flask of a 10 ml capacity was put a test tube of about 0.5 capacity containing carbon tetrachloride to saturate the reaction system with carbon tetrachloride vapor, and after the flask was tightly stoppered, preincubation was carried out at 37°C for 5 min. One ml of a test substance solution prepared at a concentration of 0.1 mg/ml in Hunk's solution was added to the suspension of liver cells, while 1 ml of Hunk's solution was added to the control. A specifically determined volume of the reaction solution was pipetted out 0 and 10 min after the initiation of reaction, respectively, and immediately centrifuged under 500 g for 30 seconds, and the ALT and AST as leached out into the supernatant liquid were determined for activity by the Lippie method. The results are shown in Table 2. Test substance ALT IU, mean±S.D. AST IU, mean±S.D. Normal group 78.7±10.6 67.8±13.9 Treated group 1573.7±212.3 1356.9±278.2 FTZ 1107.1±168.8 345.7±72.8 Thiopronine 1426.9±199.5 956.8±219.5 Glutathione 1176.1±123.7 321.7±94.4 Glycyrrhizin 1089.7±210.2 267.8±78.1 b. Antibody against rat liver cell membranes Isolated liver cells of rats were prepared by means of Segren's collagenase irrigation method, whereby a liver cell suspension was prepared at a concentration of 6 x 10 8 liver cells/ml. An Erlenmeyer flask of a 10 ml capacity in which 2 ml of the suspension had been placed was saturated with 95 % oxygen, and, after the flask was tightly stoppered, preincubation was carried out at 37°C for 5 min. One ml of a test substance solution prepared at a concentration of 0.1 mg/ml in Hunk's solution was added to the liver cell suspension, while 1 ml of Hunk's solution was added to the control, followed by incubation for another 5 min, and antiserum against rat liver cell membranes (a 50-fold diluted serum) was added. A specifically determined volume of the reaction solution was pipetted out 0 and 30 min after the initiation of reaction, respectively, and immediately centrifuged under 500 g for 30 seconds, and the ALT, AST and LDH as leached out into the supernatant liquid were determined for activity by the Lippie method. The results are shown in Table 3. Test substance ALT IU, mean±S.D. AST IU, mean±S.D. LDH IU, mean±S.D. Normal group 135.2±23.4 94.7±25.6 228.7±63.2 Treated group 2562.4±763.8 1826.2±562.4 3459.8±578.5 FTZ 1429.5±327.8 1025.8±268.4 1875.3±437.1 Thiopronine 1826.5±479.5 1623.7±432.8 2583.7±634.1 Glutathione 2257.8±581.6 1759.4±394.3 2541.1±563.4 Glycyrrhizin 1764.8±437.1 1358.4±324.1 2163.1±562.7 As is evident from Tables 1 to 3, FTZ of this invention exhibited significantly enhanced suppression against increases in activities of ALT, AST and LDH, as compared with the control compounds that have currently been in use as a therapeutic agent. 2. Anti-ulcer test Used in the test as an experiment animal were 6-week old, male rats of KBL Wistar strain that had been observed to produce no abnormalities in general conditions after being subjected to acclimatization for about one week from their purchase. (1) Stomach injury with hydrochloric acid/ethanol: Rats weighing 193 to 228 g were fasted with free access to water for 24 hours before being used in the experiment. The rats were divided into groups each consisting of 10 heads in such a way as their mean body weights were nearly uniform, treated by oral administration of hydrochloric acid/ethanol (0.15 mole hydrochloric acid solution in 80 % ethanol) at a dose of 5 ml/kg body weight and sacrificed through cervical vertebrae dislocation 1 hour after administration. The stomachs were removed and treated with formalin, and individual ulcers formed in the glandula portion of the stomach were measured in length (mm), with the measured ulcer lengths being summed for each rat. The test substance was suspended in a 0.5 % aqueous solution of sodium carboxymethylcellulose, and the suspension was given to the test group orally at a dose of 10 ml/kg body weight 30 min before administration of hydrochloric acid/ethanol, whereas the vehicle alone was applied to the control group. The results are shown in Table 4. Test substance Dose (mg/kg) Suppression rate (%) UD 50 (mg/kg) (95 % C.L.) Control group - - FTZ 50 32.1 88.7 100 53.5 (83.4∼94.3) 200 74.9 (2) Stomach injury through water-immersion constraint stress Rats weighing 183 to 235 g were fasted with free access to water for 24 hours before being used in the experiment. The rats were divided into groups each consisting of 10 heads in such a way as their mean body weights were nearly uniform, stress-loaded by soaking the animals as placed in a stress cage of Univ. of Tokyo type in a water tank at 23°C up to the xiphoid and sacrificed through cervical vertebrae dislocation 7 hours later. The stomachs were removed and treated with formalin, and individual ulcers formed in the glandula portion of the stomach were measured in length (mm), with the measured ulcer lengths being summed for each rat. The test substance was suspended in a 0.5 % aqueous solution of sodium carboxymethylcellulose, and the suspension was given to the test group orally at a dose of 10 ml/kg body weight 30 min before the water-soaking constraint, whereas the vehicle alone was applied to the control group. The results are shown in Table 5. Test substance Dose (mg/kg) Suppression rate (%) UD 50 (mg/kg) (95 % C.L.) Control group - - FTZ 50 26.4 105 100 56.1 (97.9∼113) 200 64.5 The above results suggest that the compound of this invention exhibits anti-hepatitis, liver-function improving and anti-ulcer activities, whereas 2-aminoethanesulfonic acid (taurine) was found to produce much lower corresponding effects. 3. Acute toxicity test Male, SLC:ICR (SPE) mice weighing 20 g, divided into groups each consisting of 5 heads, were treated by oral administration of the test compound suspended in gum arabic at doses of 1,000 mg/kg, 1,500 mg/kg and 2,500 mg/kg test compound, followed by observation for any abnormalities. As a result, the compound of this invention at doses up to 2,500 mg/kg LD 50 value did not cause any animal to die. Consequently, the compound of this invention was confirmed to show markedly enhanced degree of safety in comparison with its effective amount. [Industrial Applicability] Taurine, which exhibits very weak liver-function protecting activity but is nearly free from toxicity, can form a complex with zinc to thereby give the compound of this invention that greatly facilitates the intake of zinc into liver cells as compared with conventional inorganic zinc salts and develops through synergism better liver-disorder preventive activity than the existing anti-hepatitis agents. Furthermore, the finding that the compound shows a distinct mucosa-protective and restorative effect for the digestive tract, coupled with its remarkably enhanced degree of safety, indicates clinically significant utility for the compound.

Claims: A 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom). A zinc complex according to Claim 1, wherein M is sodium or potassium. A process for producing a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) comprising reacting 2-aminoethanesulfonic acid with an alkali agent and a zinc compound. A process according to Claim 3, wherein the alkali agent is an alkali metal alcoholate. A process for producing a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) comprising reacting an alkali metal salt of 2-aminoethanesulfonic acid with bis(2-aminoethanesulfonic acid)zinc salt. A pharmaceutical composition comprising a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom). A pharmaceutical composition according to Claim 6, wherein M is sodium or potassium. A 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) for therapeutic use. A zinc complex for therapeutic use according to Claim 8, wherein M is sodium or potassium. The use of a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) in the manufacture of an anti-hepatitis medicament. The use of a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) in the manufacture of a liver-function improving medicament. The use of a 2-aminoethanesulfonic acid zinc complex represented by the general formula: (wherein M is an alkali metal atom) in the manufacture of a anti-ulcer medicament. A use according to any one of Claims 10 to 12, wherein M is sodium or potassium.

Inventors: FUJIMURA HAJIME, NAGAMURA YOICHI, TANAKA TERUO, YABUUCHI TAKAHIRO, FUJIMURA, HAJIME, NAGAMURA, YOICHI, TANAKA, TERUO, YABUUCHI, TAKAHIRO
Applicants: ZAIDAN HOJIN SEISAN KAIHATSU K, ZAIDAN HOJIN SEISAN KAIHATSU KAGAKU KENKYUSHO
Application year: 1993
Main classification: C07F3
IPC codes: C07F3, A61K31, A61K33, A61P1